Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

345 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.
Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA. Nannini M, et al. Among authors: biasco g. Ther Adv Med Oncol. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19. Ther Adv Med Oncol. 2017. PMID: 29449894 Free PMC article.
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M, Fumagalli E, Palassini E, Saponara M, Di Battista M, Casali PG, Hrelia P, Cantelli-Forti G, Biasco G. Angelini S, et al. Among authors: biasco g. Pharmacol Res. 2013 Feb;68(1):1-6. doi: 10.1016/j.phrs.2012.10.015. Epub 2012 Nov 2. Pharmacol Res. 2013. PMID: 23127916
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Demetri GD, et al. Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177515 Free PMC article. Clinical Trial.
Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.
Angelini S, Ravegnini G, Nannini M, Bermejo JL, Musti M, Pantaleo MA, Fumagalli E, Venturoli N, Palassini E, Consolini N, Casali PG, Biasco G, Hrelia P. Angelini S, et al. Among authors: biasco g. Eur J Hum Genet. 2015 Jun;23(6):817-23. doi: 10.1038/ejhg.2014.198. Epub 2014 Sep 17. Eur J Hum Genet. 2015. PMID: 25227144 Free PMC article.
Targeted therapy in colorectal cancer: do we know enough?
Pantaleo MA, Palassini E, Labianca R, Biasco G. Pantaleo MA, et al. Among authors: biasco g. Dig Liver Dis. 2006 Feb;38(2):71-7. doi: 10.1016/j.dld.2005.10.004. Epub 2005 Nov 10. Dig Liver Dis. 2006. PMID: 16289975 Review.
345 results